Fulcrum Therapeutics (FULC) Accumulated Expenses: 2019-2025
Historic Accumulated Expenses for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $6.4 million.
- Fulcrum Therapeutics' Accumulated Expenses fell 22.87% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 22.87%. This contributed to the annual value of $7.7 million for FY2024, which is 11.83% down from last year.
- As of Q3 2025, Fulcrum Therapeutics' Accumulated Expenses stood at $6.4 million, which was up 30.10% from $4.9 million recorded in Q2 2025.
- Fulcrum Therapeutics' Accumulated Expenses' 5-year high stood at $12.5 million during Q2 2022, with a 5-year trough of $4.4 million in Q1 2025.
- In the last 3 years, Fulcrum Therapeutics' Accumulated Expenses had a median value of $7.2 million in 2023 and averaged $6.8 million.
- Per our database at Business Quant, Fulcrum Therapeutics' Accumulated Expenses spiked by 63.16% in 2022 and then crashed by 36.85% in 2023.
- Quarterly analysis of 5 years shows Fulcrum Therapeutics' Accumulated Expenses stood at $9.2 million in 2021, then grew by 3.47% to $9.6 million in 2022, then fell by 8.64% to $8.7 million in 2023, then fell by 11.83% to $7.7 million in 2024, then declined by 22.87% to $6.4 million in 2025.
- Its Accumulated Expenses was $6.4 million in Q3 2025, compared to $4.9 million in Q2 2025 and $4.4 million in Q1 2025.